Compare MORN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | CYTK |
|---|---|---|
| Founded | 1984 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.0B |
| IPO Year | 2005 | 2004 |
| Metric | MORN | CYTK |
|---|---|---|
| Price | $213.60 | $65.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $333.33 | $82.38 |
| AVG Volume (30 Days) | 422.6K | ★ 2.2M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 16.18 | N/A |
| EPS | ★ 8.80 | N/A |
| Revenue | ★ $2,395,400,000.00 | $87,211,000.00 |
| Revenue This Year | $8.79 | $346.43 |
| Revenue Next Year | $7.52 | $57.69 |
| P/E Ratio | $24.51 | ★ N/A |
| Revenue Growth | 7.76 | ★ 2609.26 |
| 52 Week Low | $202.89 | $29.31 |
| 52 Week High | $335.21 | $70.98 |
| Indicator | MORN | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 46.55 | 56.88 |
| Support Level | $209.41 | $58.85 |
| Resistance Level | $220.30 | $64.43 |
| Average True Range (ATR) | 5.21 | 2.90 |
| MACD | -0.18 | 0.24 |
| Stochastic Oscillator | 41.47 | 58.94 |
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.